← Back to Screener
Biofrontera Inc. Common Stock (BFRI)
Price$0.94
Value ScoreA
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)14.72%
Price vs S&P 500 (4W)-16.21%
VGM Score75.74
Market Capitalization$11.97M
All Metrics
Book Value / Share (Quarterly)$0.51
P/TBV (Annual)0.85x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)13.31%
Cash Flow / Share (Quarterly)$-0.78
Price vs S&P 500 (YTD)63.54%
Gross Margin (TTM)77.29%
Net Profit Margin (TTM)-25.66%
EPS (TTM)$-1.11
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-1.11
Revenue Growth (5Y)17.21%
EPS (Annual)$-1.04
ROI (Annual)-69.92%
Gross Margin (Annual)73.71%
Net Profit Margin (5Y Avg)-58.13%
Cash / Share (Quarterly)$0.53
Revenue Growth QoQ (YoY)17.42%
ROA (Last FY)-36.89%
Revenue Growth TTM (YoY)13.70%
EBITD / Share (TTM)$-1.01
ROE (5Y Avg)-251.27%
Operating Margin (TTM)-25.73%
Cash Flow / Share (Annual)$-1.15
P/B Ratio1.97x
P/B Ratio (Quarterly)1.55x
Net Income / Employee (Annual)$-125,400
EV / Revenue (TTM)0.24x
Net Interest Coverage (TTM)-22.36x
ROA (TTM)-49.87%
EPS Incl Extra (Annual)$-1.04
Current Ratio (Annual)1.52x
Quick Ratio (Quarterly)0.99x
3-Month Avg Trading Volume0.33M
52-Week Price Return57.94%
Revenue / Employee (TTM)$514,300
Tangible BV / Share (Quarterly)$0.29
P/S Ratio (Annual)0.29x
Asset Turnover (Annual)1.46x
52-Week High$1.19
Operating Margin (5Y Avg)-57.68%
EPS Excl Extra (Annual)$-1.04
CapEx CAGR (5Y)-35.56%
26-Week Price Return26.11%
Quick Ratio (Annual)1.21x
13-Week Price Return11.05%
Total Debt / Equity (Annual)0.44x
Current Ratio (Quarterly)1.20x
Enterprise Value$10.37M
Revenue / Share Growth (5Y)-38.64%
Asset Turnover (TTM)1.94x
Revenue / Employee (Annual)$496,500
Inventory Turnover (Annual)2.72x
Pretax Margin (Annual)-25.20%
Cash / Share (Annual)$0.55
3-Month Return Std Dev71.33%
Gross Margin (5Y Avg)53.37%
Net Income / Employee (TTM)$-132,000
EBITDA Interim CAGR (5Y)57.61%
ROE (Last FY)-100.53%
Net Interest Coverage (Annual)-22.53x
EPS Basic Excl Extra (Annual)$-1.04
Receivables Turnover (TTM)10.92x
Total Debt / Equity (Quarterly)0.78x
EPS Incl Extra (TTM)$-1.11
Receivables Turnover (Annual)6.62x
ROI (TTM)6.87%
P/S Ratio (TTM)0.28x
Pretax Margin (5Y Avg)-58.03%
Revenue / Share (Annual)$4.10
Tangible BV / Share (Annual)$0.67
Forward P/E93.86x
Price vs S&P 500 (52W)30.89%
Year-to-Date Return74.56%
5-Day Price Return12.30%
EPS Normalized (Annual)$-1.04
ROA (5Y Avg)-52.29%
Net Profit Margin (Annual)-25.26%
Month-to-Date Return12.30%
Cash Flow / Share (TTM)$-19.36
EBITD / Share (Annual)$-1.10
Operating Margin (Annual)-27.21%
LT Debt / Equity (Annual)0.44x
ROI (5Y Avg)-168.96%
LT Debt / Equity (Quarterly)0.78x
EPS Basic Excl Extra (TTM)$-1.11
P/TBV (Quarterly)2.72x
P/B Ratio (Annual)0.63x
Inventory Turnover (TTM)2.53x
Pretax Margin (TTM)-25.60%
Book Value / Share (Annual)$0.90
Price vs S&P 500 (13W)0.55%
Beta0.76x
Revenue / Share (TTM)$3.70
ROE (TTM)10.73%
52-Week Low$0.56
vGradeA
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.37est. -0.12
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BFRIBiofrontera Inc. Common Stock | A | B | B | $0.94 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Biofrontera Inc is a US-based biopharmaceutical company specializing in photodynamic therapy treatments for dermatological conditions. The company commercializes Ameluz, an FDA-approved topical photosensitizer, along with proprietary RhodoLED lamps designed for the treatment of actinic keratoses, which are pre-cancerous skin lesions. This integrated product approach combines pharmaceuticals with medical devices to address a significant market opportunity in dermatology.